Literature DB >> 28986381

Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.

Jeffrey West1, Paul K Newton2,3.   

Abstract

We extended the classical tumor regression models such as Skipper's laws and the Norton-Simon hypothesis from instantaneous regression rates to the cumulative effect over repeated cycles of chemotherapy. To achieve this end, we used a stochastic Moran process model of tumor cell kinetics coupled with a prisoner's dilemma game-theoretic cell-cell interaction model to design chemotherapeutic strategies tailored to different tumor growth characteristics. Using the Shannon entropy as a novel tool to quantify the success of dosing strategies, we contrasted MTD strategies as compared with low-dose, high-density metronomic strategies (LDM) for tumors with different growth rates. Our results show that LDM strategies outperformed MTD strategies in total tumor cell reduction. This advantage was magnified for fast-growing tumors that thrive on long periods of unhindered growth without chemotherapy drugs present and was not evident after a single cycle of chemotherapy but grew after each subsequent cycle of repeated chemotherapy. The evolutionary growth/regression model introduced in this article agrees well with murine models. Overall, this model supports the concept of designing different chemotherapeutic schedules for tumors with different growth rates and develops quantitative tools to optimize these schedules for maintaining low-volume tumors. Cancer Res; 77(23); 6717-28. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28986381      PMCID: PMC5712269          DOI: 10.1158/0008-5472.CAN-17-1120

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  The evolutionary origin of cooperators and defectors.

Authors:  Michael Doebeli; Christoph Hauert; Timothy Killingback
Journal:  Science       Date:  2004-10-29       Impact factor: 47.728

3.  An evolutionary hybrid cellular automaton model of solid tumour growth.

Authors:  P Gerlee; A R A Anderson
Journal:  J Theor Biol       Date:  2007-02-12       Impact factor: 2.691

Review 4.  Evolution of cooperation among tumor cells.

Authors:  Robert Axelrod; David E Axelrod; Kenneth J Pienta
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

5.  A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.

Authors:  David R Spigel; F Anthony Greco; Howard A Burris; Dianna L Shipley; Bobby L Clark; Robert C Whorf; Edward R Arrowsmith; John D Hainsworth
Journal:  Clin Lung Cancer       Date:  2011-04-28       Impact factor: 4.785

Review 6.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

Review 8.  Intratumor heterogeneity: evolution through space and time.

Authors:  Charles Swanton
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

9.  Evolutionary dynamics of cancer in response to targeted combination therapy.

Authors:  Ivana Bozic; Johannes G Reiter; Benjamin Allen; Tibor Antal; Krishnendu Chatterjee; Preya Shah; Yo Sup Moon; Amin Yaqubie; Nicole Kelly; Dung T Le; Evan J Lipson; Paul B Chapman; Luis A Diaz; Bert Vogelstein; Martin A Nowak
Journal:  Elife       Date:  2013-06-25       Impact factor: 8.140

10.  The use of positron emission tomography/computed tomography imaging in radiation therapy: a phantom study for setting internal target volume of biological target volume.

Authors:  Wataru Kawakami; Akihiro Takemura; Kunihiko Yokoyama; Kenichi Nakajima; Syoichi Yokoyama; Kichiro Koshida
Journal:  Radiat Oncol       Date:  2015-01-08       Impact factor: 3.481

View more
  5 in total

1.  The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.

Authors:  Jeffrey West; Mark Robertson-Tessi; Kimberly Luddy; Derek S Park; Drew F K Williamson; Cathal Harmon; Hung T Khong; Joel Brown; Alexander R A Anderson
Journal:  JCO Clin Cancer Inform       Date:  2019-02

2.  Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.

Authors:  Louis T Curtis; Victor H van Berkel; Hermann B Frieboes
Journal:  J Theor Biol       Date:  2018-04-01       Impact factor: 2.691

Review 3.  The pro-tumorigenic host response to cancer therapies.

Authors:  Yuval Shaked
Journal:  Nat Rev Cancer       Date:  2019-10-23       Impact factor: 60.716

4.  Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction.

Authors:  Zain Khurshid; Hojjat Ahmadzadehfar; Florian C Gaertner; László Papp; Norbert Zsóter; Markus Essler; Ralph A Bundschuh
Journal:  Oncotarget       Date:  2018-09-07

5.  Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach.

Authors:  Farshad Moradi Kashkooli; M Soltani
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.